Medicines for Ireland (MFI), which represents suppliers of generic, biosimilar and value-added medicines, has called for priority to be given to investments in medicines and systems that deliver value for patients and the State. MFI’s election manifesto, which was published during the recent election campaign, emphasises the importance of a resilient and sustainable generics, biosimilars, and value-added medicines industry. MFI has called for, patent reform for fair competition; access to essential and affordable medicines; and an industry fit for the green, digital era.

MFI says, “the escalating costs of managing chronic diseases and long-term care are placing an unsustainable burden on our healthcare system. By prioritising the use of generics and biosimilars, we can alleviate this pressure and ensure that all patients have access to the medicines they need. Our manifesto provides a roadmap for achieving this, and we call on all political parties to support these vital reforms.”

MFI member companies include Accord Healthcare, Celltrion Healthcare, Clonmel Healthcare, Consilient Health, Fannin, Fresenius Kabi, Pinewood Healthcare, Sandoz trading as Rowex, Teva, and Viatris.